medRxiv
October 19, 2026
Joel Gelernter, Jack Hirsch, Cassie M. Overstreet et al.
preprint
Frequent nightmares affect roughly 2-6% of the population and may reflect underlying psychopathology, such as post-traumatic stress disorder (PTSD), or, when recurrent and distressing, be diagnosed as nightmare disorder (ND). The genetic basis of nightmares remains poorly understood. We performed a genome-wide association study (GWAS) meta-analysis of nightmare frequency (NF) across 207,243...
Neuropsychopharmacology
June 3, 2023
Or Duek, Nachshon Korem, Yutong Li et al.
71 citations
NMDA receptor antagonists have a vital role in extinction, learning, and reconsolidation processes. During the reconsolidation window, memories are activated into a labile state and can be reconsolidated in an altered form. This concept might have significant clinical implications in treating PTSD. In this pilot study we tested the potential of a single infusion of ketamine, followed by brief...
European Psychiatry
July 17, 2016
Andreas Heinz, Martin Voss, Stephen M. Lawrie et al.
84 citations
BACKGROUND: First rank symptoms (FRS) of schizophrenia have been used for decades for diagnostic purposes. In the new version of the DSM-5, the American Psychiatric Association (APA) has abolished any further reference to FRS of schizophrenia and treats them like any other "criterion A" symptom (e.g. any kind of hallucination or delusion) with regard to their diagnostic implication. The ICD-10...
Frontiers in Psychiatry
2013
Alan Anticevic, Michael W. Cole, Grega Repovš et al.
78 citations
Neuropsychiatric diseases such as schizophrenia and bipolar illness alter the structure and function of distributed neural networks. Functional neuroimaging tools have evolved sufficiently to reliably detect system-level disturbances in neural networks. This review focuses on recent findings in schizophrenia and bipolar illness using resting-state neuroimaging, an advantageous approach for...
Biological Psychiatry
March 15, 2005
Deepak Cyril D'Souza, Walid Michel Abi-Saab, Steven Madonick et al.
Recent advances in the neurobiology of cannabinoids have renewed interest in the association between cannabis and psychotic disorders. In a 3-day, double-blind, randomized, placebo-controlled study, the behavioral, cognitive, motor, and endocrine effects of 0 mg, 2.5 mg, and 5 mg intravenous Delta-9-tetrahydrocannabinol (Delta-9-THC) were characterized in 13 stable, antipsychotic-treated...
Neuropsychopharmacology
August 2004
Deepak Cyril D'Souza, Edward Perry, Lisa Macdougall et al.
Recent advances in the understanding of brain cannabinoid receptor function have renewed interest in the association between cannabinoid compounds and psychosis. In a 3-day, double-blind, randomized, and counterbalanced study, the behavioral, cognitive, and endocrine effects of 0, 2.5, and 5 mg intravenous delta-9-tetrahydrocannabinol (Delta-9-THC) were characterized in 22 healthy individuals,...
Cambridge University Press eBooks
May 27, 2004
Deepak Cyril D’souza, Hyun Sang Cho, Edward Belk Perry et al.
32 citations
Hypotheses relating to the association between cannabis and psychosis may be divided into two groups. The exogenous hypothesis, which has received far greater attention, suggests that the consumption of cannabinoid compounds produces psychotic disorders by mechanisms that are extrinsic to the pathophysiology of naturally occurring psychoses. As discussed elsewhere in this book, converging...